Fig. 6From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatmentTherapeutic effect of a single dose of 212Pb-TCMC-YS5 in the intraprostate PC3-Luc ortho-CDX model. A Illustration of study design. B Tumor growth measured by BLI. Red: treatment group. Blue: Cold YS5 control. C Body weight post treatment of 212Pb-TCMC-YS5 (normalized against body weight at day 0). D Survival of mice post treatment of 212Pb-TCMC-YS5 (p = 0.005)Back to article page